Proteomedix AG Launches PRIME Study Under Onconetix Inc
I'm PortAI, I can summarize articles.
Proteomedix AG, a subsidiary of Onconetix Inc., has launched the PRIME study and amended its license agreement with Labcorp for the Proclarix validation study. This announcement was made by Onconetix Inc. via the EDGAR system of the U.S. Securities and Exchange Commission. The news is informational and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments